BioCentury
ARTICLE | Clinical News

Neon points to PFS, biomarkers as signs of neoantigen activity in single-arm combo trial

July 15, 2019 11:58 PM UTC

With Phase Ib data on its neoantigen cancer vaccine plus Opdivo announced Monday, Neon is the latest company to suggest its immuno-oncology candidate improves on the efficacy of checkpoint inhibitor alone by comparing a single-arm combination study to historical controls. The company cites the combo's effects on PFS across three tumor types, and on mechanistic biomarkers like epitope spreading, as signs the combo will show benefit over monotherapy in forthcoming randomized studies.

Neon Therapeutics Inc. (NASDAQ:NTGN) announced the combination of its personalized peptide neoantigen vaccine NEO-PV-01 and Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) improved progression-free survival (PFS) in checkpoint naïve metastatic melanoma, non-small cell lung cancer (NSCLC) and bladder cancer patients compared with historical studies of Opdivo alone in patient populations with similar baseline characteristics. Shares in the company gained $0.30 to $4.62 on Monday...